Learn More
OBJECTIVE This pilot study investigates the dissolution profile, tolerability, and acceptability of an orally disintegrating olanzapine tablet in patients with schizophrenia. METHOD Eleven patients with schizophrenia stabilized on oral olanzapine (mean dosage 12.7 mg daily [SD5.2]) were given an orally disintegrating olanzapine tablet, rather than their(More)
Serial verbal learning task (explicit long-term memory) and verbal fluency (generation of a response) are tests that are usually severely impaired in schizophrenia. Despite the growing literature supporting the clinical efficacy of olanzapine, psychiatrists still question its cognitive consequences. This study assessed the efficacy of olanzapine on(More)
This pilot longitudinal study using measures from parents and teachers evaluated the effects of flexible doses of atomoxetine (ATX) on neuropsychological and functional outcomes in 21 children with attention-deficit/hyperactivity disorder (ADHD) (mean age, 8.0 +/- 1.3 years; inattentive subtype, 71.4%; combined subtype, 28.6%). Among 16 children completing(More)
BACKGROUND This study was conducted to prospectively examine the effect of switching from risperidone to olanzapine on female schizophrenia patients who experienced menstrual disturbances, galactorrhea, and/or sexual dysfunction. METHOD Twenty female patients with DSM-IV schizophrenia who were taking risperidone and were suffering from menstrual(More)
Violence and persistent aggression are serious problems in the general population and among certain psychiatric patients. Violence and persistent aggression have been associated with suicidal ideation and substance abuse, characteristics of chronically ill, and in many instances, treatment-resistant schizophrenia individuals. Assessment of dangerousness in(More)
BACKGROUND Controversy surrounds the relationship between tardive dyskinesia (TD) and symptoms of schizophrenia. While some studies reported that negative symptoms of schizophrenia may be a risk factor for TD, others reported a relationship between TD and positive symptoms. METHOD Eighty-four patients were studied, of whom 47 met criteria for TD. Clinical(More)
BACKGROUND The relatively short durations of the initial pivotal randomized placebo-controlled trials involving atomoxetine HCl for the treatment of attention-deficit/hyperactivity disorder (ADHD) provided limited insight into the time courses of ADHD core symptom responses to this nonstimulant, selective norepinephrine reuptake inhibitor. The aim of this(More)